Drugs / AB102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07662057 | Jul → Dec 2026 expected | — | Arcus Biosciences, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07662057 ↗ |
| Route | Oral | “Administered orally as specified in the treatment arm” NCT07662057 ↗ |